Mass. High Court Dismisses Action Targeting Genzyme’s Arthritis Device



DOCUMENTS
  • Opinion


BOSTON — Massachusetts’ highest court has dismissed an action targeting Genzyme Corp.’s arthritis product, ruling that while the claims are not preempted by federal law, the plaintiff failed to adequately plead causation.

In a Jan. 29 opinion, the Massachusetts Supreme Judicial Court found the complaint failed to provide any factual allegations to back the plaintiff’s “labels and conclusions.”

To treat the osteoarthritis in her knees, Patricia Dunn received two injections of Genzyme’s Synvisc-One on June 8, 2015, one in each knee. Synvisc-One, a Class III medical device, was approved by the Food and Drug Administration in 2009 for the treatment …






UPCOMING CONFERENCES




HarrisMartin's Webinar Series: Baby Food Litigation

April 08, 2021 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS



HarrisMartin's Webinar Series: 3M Combat Arms Earplugs - Litigating with the Government as a Witness

March 12, 2021 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS